The first thing you need to do is choose a news reader, if you already don't have one. This is a piece of software that checks feeds you have requested and lets you read any new articles that have been added. There are various types of news reader. You should choose one that will work with your computer’s operating system.
When you have chosen a news reader, you can decide what content you want to keep up to date with. Please choose from below:
|Albania||Bosnia and Herzegovina||Bulgaria||Croatia|
|INTERVIEWS BY BALKANS.COM|
Alternatively, you can paste one of the BBN RSS URLs into a new feed in your news reader.
|E-mail article||Save||Additional News in English||Još vesti na Srpskom||Επιπλέον ειδήσεις στα Ελληνικά||Text|
Hurriyet - Czech generic drugs company Zentiva has announced its plans to shift the majority of its production to its plant in Turkey in a bid to make the country an export base for over 34 countries. A subsidiary of French pharma giant Sanofi, Zentiva acquired the generics business of Turkish drug manufacturer Eczacibasi in 2007. Following its entry, the generics unit of Sanofi has turned the Luleburgaz, Kirklareli plant in western Turkey into one of the biggest research and development (R&D) labs of the group.
“Zentiva’s Turkish plant will be a supply base for generic drugs after their production moves to Turkey,” according to Zentiva’s President Jérôme Silvestre. Speaking to the press at the company’s headquarters in Prague, Czech Republic, Zentiva head said that Luleburgaz plant was issued with quality compliance awards from 13 countries including the US, Germany, Australia and Denmark, effectively becoming a production hub for the growing global generics markets.
Generics constitute more than 40 percent of the global pharma market with a volume of USD 100 billion. Generic drugs sector, with much lower development and production costs, continue to thrive especially in emerging countries. Around 80 percent of drug sales in Turkey consist of generics, making up of about 50 percent of the sectoral turnover. The country has witnessed sizeable takeovers and partnerships in pharma sector in recent years, the latest being the acquisition of local generics manufacturer Mustafa Nevzat by US biotech giant Amgen for USD 700 million. Source: IIT
Related News in English
Povezane vesti na srpskom
Συναφείς Ειδήσεις στα Ελληνικά